NL-OMON52825
Recruiting
Not Applicable
nderstanding mechanisms of prevention of depression: a mechanistic cross-over trial of mindfulness vs. fantasizing to reduce perseverative cognition underlying vulnerability for depression - MINDCOG
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- depression
- Sponsor
- niversitair Medisch Centrum Groningen
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All participants will be between 18 and 60 years of age. Participating patients
- •will have experienced at least two major depressive episodes (experienced in
- •the past ten years) and are in (partial or complete) remission from a
- •depressive episode (for more than 2 months).
Exclusion Criteria
- •Participants should not have any current DSM\-5 diagnoses, should currently not
- •use anti\-depressant medication (i.e. \>4 weeks) have not received protocolized
- •preventive cognitive therapy for their last episode or have recent (daily
- •practice) experiences with mindfulness. Healthy participants should furthermore
- •show no life\-time psychopathology.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Predicting and Understanding Depression Prevention Techniques: a mechanistic cross-over trial of mindfulness vs. fantasizing to reduce vulnerability for depressiomajor depressive disorderNL-OMON22588niversity Medical Center Groningen100
Completed
Not Applicable
Depression and anxiety: Indicated Prevention in homes for the elderlyISRCTN27540731VU University Medical Center/EMGO-Institute (The Netherlands)180
Recruiting
Not Applicable
Mechanisms of Change of Positive Interventions in Reducing Vulnerability for DepressionDepression in RemissionNCT06145984University Medical Center Groningen100
Recruiting
Not Applicable
Mechanisms Underlying Antidepressant Effects of Physical ActivityDepressionNCT06387732University College, London250
Active, not recruiting
Phase 1
Antidepressant for the prevention of DEPression following first episode Psychosis trialPatients with First Episode Psychosis.Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2020-002787-32-GBniversity of Birmingham508